Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Moberg Pharma AB's Goodwill for the quarter that ended in Mar. 2024 was kr0.00 Mil. Moberg Pharma AB's Total Assets for the quarter that ended in Mar. 2024 was kr632.03 Mil.
Therefore, Moberg Pharma AB's Goodwill to Asset Ratio for the quarter that ended in Mar. 2024 was 0.00.
Moberg Pharma AB Goodwill-to-Asset Historical Data
The historical data trend for Moberg Pharma AB's Goodwill-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Moberg Pharma AB's Goodwill-to-Asset
For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moberg Pharma AB's Goodwill-to-Asset Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Goodwill-to-Asset distribution charts can be found below:
* The bar in red indicates where Moberg Pharma AB's Goodwill-to-Asset falls into.
Moberg Pharma AB Goodwill-to-Asset Calculation
Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.
It is calculated by dividing goodwill by total assets.
Moberg Pharma AB's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moberg Pharma AB (OSTO:MOB) Goodwill-to-Asset Explanation
If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.
Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.
Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.
Moberg Pharma AB Goodwill-to-Asset Related Terms
Thank you for viewing the detailed overview of Moberg Pharma AB's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Moberg Pharma has commercial agreements with partners in Europe and Canada, among others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:MOB has been successfully added to your 